Natera (NTRA) stock surged after reporting "blowout" Q2 results, driven by strong Signatera cancer test volume
An analyst noted "blowout volume" for Natera's Signatera cancer-detecting blood test in the second quarter, which saw 34,000 tests performed.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
XRP is testing the $1.50 resistance level, a key threshold that has capped its advances for roughly 230 days, with a break potentially leading to $1.80+
-
2
Seoul stocks rise 1.65% on chip gains despite Middle East tensions
-
3
Binance Stock Trading Platform Adds 25 New Stocks
-
4
Morgan Stanley’s Wilson Says US Stocks Risk 7% Drop in Near Term
-
5
US equity futures rise, led by AI stocks; oil prices fall over 2% to around $101; US Treasury yields decline; US and Chinese officials discuss AI national security "notification mechanism."
-
6
Commodities trader Trafigura plans to float its supertanker arm Volare Shipping in Oslo, marking the business's first IPO
-
7
Central Bank Digital Currency (CBDC) In-Depth Analysis: Global Progress and Impact
-
8
JPMorgan CEO Dimon to Visit India This Week, Ramping Up Push for Deal Boom
-
9
BiblePay (BBP) Cryptocurrency Analysis: Charitable Mission, Technical Features, and Market Status
-
10
Novo Nordisk, the Danish pharmaceutical giant, saw its shares fall by 7% despite setting a $23 billion sales target for its weight-loss drug.
Markets Today
Recommended Reading




